Newsroom
Pediatric Praziquantel Consortium nominated for Prix Galien Bridges Award for Best Public Sector Innovation
The Pediatric Praziquantel Consortium has been nominated for the 2025 Prix Galien Bridges Award in the Public Sector Innovation category. The Prix Galien Awards, often regarded as the “Nobel Prize for biopharmaceutical research,” recognize outstanding achievements that improve human health through scientific innovation.
The Consortium’s nomination highlights the collaborative effort behind the development of our new child-friendly formulation of praziquantel designed to enable treatment of preschool-aged children affected by schistosomiasis — a parasitic disease that impacts more than 250 million people worldwide.
Since its establishment in 2012, the Pediatric Praziquantel Consortium has united partners from academia, industry, public health, and non-profit sectors to achieve a shared mission: to make a safe, effective, and accessible treatment available for the youngest children in endemic countries.
Winners of the Prix Galien Bridges Awards will be announced at a ceremony on 5 December 2025 at the Nobel Forum, Karolinska Institutet, Stockholm, Sweden.
For more information about the Prix Galien Bridges Awards, visit: www.galienfoundation.org.